Skip to main content
Edwin Kim, MD, MS

February 25, 2024

Drug in OUtMATCH Clinical Trial FDA-Approved for the Reduction of Allergic Reactions from Accidental Food Exposures

Stage one results from the OUtMATCH clinical trial, published in the New England Journal of Medicine, show that a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as age one could consume without an allergic reaction. Edwin Kim, MD, Corinne Keet, MD, PhD, and Mike Kulis, PhD, are contributing authors.